Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 2,460 | 5日内发货 | ||
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment. |
体外活性 | Nuvenzepine is almost equipotent to pirenzepine in competitively preventing bethanechol-induced gall-bladder contractions and it shows a four-fold higher potency than pirenzepine in blocking vagal-stimulated tracheal constrictions. Nuvenzepine displays a four-fold higher affinity than pirenzepine in competitively antagonizing acetylcholine-induced contractions on isolated ileal musculature and on longitudinal ileum dispersed cells [1]. |
体内活性 | Nuvenzepine is also active, unlike pirenzepine, on colonic stimulated motility. In anaesthetized cats, intraduodenally administration of Nuvenzepine shows a long-lasting and dose-dependent inhibition of neostigmine-induced intestinal motility. Nuvenzepine has been found to be very active in inhibiting gastric acid secretion and intestinal hypermotility in rats, with very slight atropine-like side effects. The oral absorption rate is relatively slow, that the absolute bioavailability is 30 to 40%, that the elimination rate is slow and there is no accumulation in the body, and that there is very little metabolism. Nuvenzepine displays a potency 10 times greater than that of pirenzepine on ileal motor activity. Nuvenzepine inhibits pentagastrin-stimulated gastric acid secretion resulting 25-30 times more potent than pirenzepine in conscious cats [2][3]. |
分子量 | 336.39 |
分子式 | C19H20N4O2 |
CAS No. | 96487-37-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Nuvenzepine 96487-37-5 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Inhibitor inhibitor inhibit